Graph Neural Networks for COVID-19 Drug Discovery

20Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Deep learning has led to major advances in fields like natural language processing, computer vision, and other Euclidean data domains. Yet, many important fields have data defined on irregular domains, requiring graphs to be explicitly modeled. One such application is drug discovery. Recently, research has found that using graph neural network (GNN) models, given enough data, can perform better than using human-engineered fingerprints or descriptors in predicting molecular properties of potential antibiotics.We explore these state-of-the-art AI models on predicting desirable molecular properties for drugs that can inhibit SARS-CoV-2. We build upon the GNN models with ideas from recent breakthroughs in geometric deep learning, inspired by the topologies of the molecules. In this poster paper, we present an overview of the drug discovery framework, drug-target interaction framework, and GNNs. Preliminary results on two COVID-19 related datasets are encouraging, achieving a ROC-AUC of 0.72 for FDA-approved chemical library screened against SARS-CoV-2 in vitro.

Cite

CITATION STYLE

APA

Cheung, M., & Moura, J. M. F. (2020). Graph Neural Networks for COVID-19 Drug Discovery. In Proceedings - 2020 IEEE International Conference on Big Data, Big Data 2020 (pp. 5646–5648). Institute of Electrical and Electronics Engineers Inc. https://doi.org/10.1109/BigData50022.2020.9378164

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free